IBO

Impact BioMedical, Inc.

IBO

Market cap $7.63M

Overview Fund Activity

0.6315 USD

-0.0503

7.38%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

0.6600

+0.0285

4.51%

1 day

-7.38%

5 days

-0.08%

1 month

7.03%

3 months

41.43%

6 months

3.51%

Year to date

-58.99%

1 year

-72.9%

5 years

-76.44%

10 years

-76.44%

About: Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.

Employees: 8

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

20% more funds holding

Funds holding: 15 [Q1] → 18 (+3) [Q2]

1.01% more ownership

Funds ownership: 2.89% [Q1] → 3.9% (+1.01%) [Q2]

0% more capital invested

Capital invested by funds: $304K [Q1] → $305K (+$837) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

See Fund Rankings

Financial journalist opinion

Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO's 3F™ technology platform.

Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

IBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Impact BioMedical Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Impact BioMedical Inc. (NYSE American: IBO) and Dr Ashleys Limited is fair to Impact shareholders. Halper Sadeh encourages Impact shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Impact and its board violated.

IBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Impact BioMedical Inc. Is Fair to Shareholders

Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merger and share exchange agreement (the “Merger Agreement”) on June 21, 2025 to enter into a strategic merger transaction (the “Transaction”). Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly formed combined entity (the “PubCo”) traded on the NYSE American under the name “Dr Ashleys Limited.”

Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

Impact Biomedical Inc. Announcement Stock Activity/Pricing

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.

Impact Biomedical Inc. Announcement Stock Activity/Pricing

Impact BioMedical Inc. to Present at The Microcap Conference

HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as well as their uses in treating inflammatory related diseases.

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential.

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled “Insect Repelling Composition” developed within IBO's 3F™ technology platform.

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO”.

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Impact BioMedical Inc. Announces Pricing of Initial Public Offering

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares are expected to begin trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO.”

Impact BioMedical Inc. Announces Pricing of Initial Public Offering

See News Rankings

Charts implemented using Lightweight Charts™